Abstract library

130 results for "van Nederveen".
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: MD, MSc Dirk-Jan van Beek
#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt
#981 Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up
Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Drs Kimberly Kamp
Keywords: PTH, PTHrP, net, hypercalcemia
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...
#3010 International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: drs Charlotte Heidsma
#2738 Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma
Introduction: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. Due to its low incidence and wide tissue distribution few representative preclinical models are available
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD PhD Margot Tesselaar
#2913 The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study
Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Mark van Treijen
#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Elin Pauwels
#2968 Incidence of Rectal NEN and Adherence to Pathology Classification Rules and Treatment Guidelines: Results of the Population Based Cancer Registry in Belgium
Introduction: Classification of rectal NEN (rNEN) changed significantly over the years.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Karen Geboes